Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.32 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.32 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.32 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.32 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.32 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173880 | 0.79 | PARP1 (0.46) | SCN9ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5198009 | 0.79 | PDK2 (0.37) | NR4A2PDK2PDK4PTGER4RIPK1 | |
| SCHEMBL12377184 | 0.74 | TUBB4A (0.39) | NR4A2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1174317 | 0.74 | SCN9A (0.44) | SCN9ANR4A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12377145 | 0.73 | HTR2A (0.40) | HTR2A | |
| SCHEMBL2288741 | 0.73 | CNR1 (0.37) | NR4A2CYP2D6CYP2C9CYP2C19GSK3A | |
| SCHEMBL12377187 | 0.72 | SLC6A3 (0.36) | NR4A2RIPK1HTR2A | |
| SCHEMBL12869673 | 0.71 | SCN9A (0.39) | SCN9ANR4A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6387931 | 0.70 | HTR2A (0.44) | SCN9ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11566905 | 0.68 | KDM4E (0.50) | CYP2D6CYP2C9CYP2C19RIPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| EP-1587585-B1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES | BOEHRINGER INGELHEIM INT (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7323470-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-7323470-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7098231-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-29 | — | — | US | disclosed |
| US-20060189672-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1587585-A1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES | Boehringer Ingelheim International GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-20040186125-A1 | E.g , 3-cyclohexyl-2-furan-3-yl-1Hindole-5-carboxylic acid; hepatitis C viricides that target RNA dependent RNA polymerases (Ns5B) in mammals, an enzyme essential to viral replication; used in conjunction with an mmunomodulatory agent, such as beta -, delta - gamma -, and omega -interferon | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004064925-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189672-A1 | Viral polymerase inhibitors | POLM, POLR2A, POLR2H | SCN9A 1363/4885NR4A2 2671/4885PDK2 3114/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | SCN9A 837/4885NR4A2 3550/4885PDK2 3704/4885 |
| US-20080119490-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | SCN9A 1217/4885NR4A2 2704/4885PDK2 3236/4885 |
| US-20040186125-A1 | E.g , 3-cyclohexyl-2-furan-3-yl-1Hindole-5-carboxylic acid; hepatitis C viricides that target RNA dependent RNA polymerases (Ns5B) in mammals, an enzyme essential to viral replication; used in conjunction with an mmunomodulatory agent, such as beta -, delta - gamma -, and omega -interferon | IFNAR1, IFNG, EIF2AK2 | SCN9A 2239/4885NR4A2 2322/4885PDK2 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.